David Molkentine

1.3k total citations
30 papers, 708 citations indexed

About

David Molkentine is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Molkentine has authored 30 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Molkentine's work include Cancer-related Molecular Pathways (16 papers), Colorectal and Anal Carcinomas (5 papers) and Lung Cancer Treatments and Mutations (5 papers). David Molkentine is often cited by papers focused on Cancer-related Molecular Pathways (16 papers), Colorectal and Anal Carcinomas (5 papers) and Lung Cancer Treatments and Mutations (5 papers). David Molkentine collaborates with scholars based in United States, Switzerland and India. David Molkentine's co-authors include Uma Raju, Luka Milas, John V. Heymach, Jeffrey N. Myers, Oliver Riesterer, Uma Giri, Heath D. Skinner, David R. Valdecanas, Raymond E. Meyn and Lauren A. Byers and has published in prestigious journals such as Cancer Research, Oncogene and Clinical Cancer Research.

In The Last Decade

David Molkentine

29 papers receiving 701 citations

Peers

Countries citing papers authored by David Molkentine

Since Specialization

Citations

This map shows the geographic impact of David Molkentine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Molkentine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Molkentine more than expected).

Fields of papers citing papers by David Molkentine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Molkentine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Molkentine. The network helps show where David Molkentine may publish in the future.

Co-authorship network of co-authors of David Molkentine

This figure shows the co-authorship network connecting the top 25 collaborators of David Molkentine. A scholar is included among the top collaborators of David Molkentine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Molkentine. David Molkentine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Th2 Cells Are Associated with Tumor Recurrence Following Radiation 2024 ·Cancers ·(unknown), Riyue Bao, Phillip M. Pifer, David Molkentine, Jessica M. Molkentine, (unknown), Beth M. Beadle, John V. Heymach, Jason J. Luke, Robert L. Ferris, Curtis R. Pickering, Jing Wang, Ravi B. Patel, Heath D. Skinner	2
2	FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner 2023 ·Clinical Cancer Research ·Phillip M. Pifer, Liangpeng Yang, Manish Kumar, Tongxin Xie, Mitchell J. Frederick, (unknown), Beth M. Beadle, David Molkentine, Jessica M. Molkentine, (unknown), (unknown), Abdullah A. Osman, Brian J. Leibowitz, Jeffrey N. Myers, Curtis R. Pickering, Vlad C. Sandulache, John V. Heymach, Heath D. Skinner	13
3	Non-Canonical p16-SP1 Signaling in Head and Neck Cancer Potentially Affects Cell Plasticity 2023 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Sreyashi Basu, (unknown), Phillip M. Pifer, (unknown), David Molkentine, Heath D. Skinner	1
4	p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade 2021 ·Cancer Research ·David Molkentine, Jessica M. Molkentine, Kathleen A. Bridges, David R. Valdecanas, (unknown), (unknown), (unknown), Manish Kumar, Liangpeng Yang, (unknown), Phillip M. Pifer, Vlad C. Sandulache, Aakash Sheth, Beth M. Beadle, Howard D. Thames, Kathryn A. Mason, Curtis R. Pickering, Raymond E. Meyn, Heath D. Skinner	22
5	Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints 2020 ·International Journal of Radiation Biology ·Jessica M. Molkentine, David Molkentine, Kathleen A. Bridges, Tongxin Xie, Liangpeng Yang, Aakash Sheth, Timothy P. Heffernan, D.A. Clump, (unknown), Robert L. Ferris, Jeffrey N. Myers, Mitchell J. Frederick, Kathryn A. Mason, Raymond E. Meyn, Curtis R. Pickering, Heath D. Skinner	29
6	BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer 2017 ·Clinical Cancer Research ·(unknown), Manish Kumar, Liangpeng Yang, David Molkentine, David R. Valdecanas, Shiying Yu, Raymond E. Meyn, John V. Heymach, Heath D. Skinner	20
7	Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer 2017 ·Clinical Cancer Research ·Heath D. Skinner, Uma Giri, Liang Yang, Manish Kumar, Ying Liu, Michael D. Story, Curtis R. Pickering, Lauren A. Byers, Michelle D. Williams, Jing Wang, Li Shen, Suk Young Yoo, You Hong Fan, David Molkentine, Beth M. Beadle, Raymond E. Meyn, Jeffrey N. Myers, John V. Heymach	86
8	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer 2016 ·Clinical Cancer Research ·Heath D. Skinner, Uma Giri, Liang Yang, Sang Hyeok Woo, Michael D. Story, Curtis R. Pickering, Lauren A. Byers, Michelle D. Williams, Adel K. El‐Naggar, Jing Wang, Lixia Diao, Li Shen, You Hong Fan, David Molkentine, Beth M. Beadle, Raymond E. Meyn, Jeffrey N. Myers, John V. Heymach	55
9	Biological responses of human solid tumor cells to X‐ray irradiation within a 1.5‐Tesla magnetic field generated by a magnetic resonance imaging–linear accelerator 2016 ·Bioelectromagnetics ·Li Wang, (unknown), Zhifei Wen, Marco van Vulpen, David Molkentine, J G M Kok, Steven H. Lin, Roel Broekhuizen, Kie‐Kian Ang, Niels Bovenschen, Bas W. Raaymakers, Steven J. Frank	11
10	TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects 2016 ·Oncogene ·(unknown), Peijing Zhang, David Molkentine, (unknown), Jessica M. Molkentine, Hai‐long Piao, Uma Raju, J. Zhang, David R. Valdecanas, (unknown), Howard D. Thames, Thomas A. Buchholz, (unknown), Li Ma, Kathryn A. Mason, K. Kian Ang, R.E. Meyn, Heath D. Skinner	39
11	Preclinical Studies of Metformin Reveal Radiosensitization for Human Small Cell Lung Cancer In Vitro But Apparent Antagonism In Vivo 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Tatiana Rabin, Ritsuko Komaki, Uma Raju, (unknown), David Molkentine, David R. Valdecanas, Jessica M. Molkentine, K.A. Mason, M. OʼReilly	2
12	Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways 2012 ·Radiotherapy and Oncology ·Uma Raju, Oliver Riesterer, Zhiqiang Wang, David Molkentine, Jessica M. Molkentine, Faye M. Johnson, Bonnie S. Glisson, Luka Milas, K. Kian Ang	48
13	C-Met Inhibitor MK-8003 Radiosensitizes c-Met–Expressing Non–Small-Cell Lung Cancer Cells With Radiation-Induced c-Met–Expression 2012 ·Journal of Thoracic Oncology ·Vikas Bhardwaj, Yanai Zhan, María Angélica Cortez, Kie Kian Ang, David Molkentine, Anupama Munshi, Uma Raju, Ritsuko Komaki, John V. Heymach, James W. Welsh	38
14	Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro 2011 ·Clinical Cancer Research ·Daisuke Sano, Fumihiko Matsumoto, David R. Valdecanas, Mei Zhao, David Molkentine, Yoko Takahashi, Ehab Y. Hanna, Vali Papadimitrakopoulou, John V. Heymach, Luka Milas, Jeffrey N. Myers	59
15	DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy 2011 ·Clinical Cancer Research ·Benjamin J. Moeller, John S. Yordy, Michelle D. Williams, Uma Giri, Uma Raju, David Molkentine, Lauren A. Byers, John V. Heymach, Michael D. Story, J. Jack Lee, Erich M. Sturgis, Randal S. Weber, Adam S. Garden, (unknown), David A. Schwartz	75
16	Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells. 2011 ·PubMed ·Li Wang, Uma Raju, Luka Milas, David Molkentine, Zhen Zhang, Peiying Yang, Lorenzo Cohen, Zhiqiang Meng, Zhongxing Liao	36
17	Combination of Anti-IGF-1R Antibody A12 and Ionizing Radiation in Upper Respiratory Tract Cancers 2010 ·International Journal of Radiation OncologyBiologyPhysics ·Oliver Riesterer, Qiuan Yang, Uma Raju, Mylin A. Torres, David Molkentine, (unknown), David R. Valdecanas, Luka Milas, K. Kian Ang	33
18	AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo 2010 ·Investigational New Drugs ·Mylin A. Torres, Uma Raju, David Molkentine, Oliver Riesterer, Luka Milas, K. Kian Ang	21
19	Abstract 5674: Huachansu, an extract from toad skin, strongly enhances radiosensitivity of human lung cancer cell lines 2010 ·Cancer Research ·Li Wang, Luka Milas, Uma Raju, David Molkentine, Peiying Yang, Lorenzo Cohen, Zhongxing Liao	1
20	A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe 2009 ·Investigational New Drugs ·Oliver Riesterer, Fumihiko Matsumoto, Li Wang, (unknown), David Molkentine, Uma Giri, Luka Milas, Uma Raju	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact